{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/8cf4cec7-5a0f-49c5-8ec9-36941b5c6b6e/aa809109-ca5e-47d5-bfdb-1c85747f4257?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Cambrian Biopharma's James Peyer: \"70 will be the new 50\"","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/61ba0b311a8cbef1d93cf121/1786085106618-3cf925e6-1cc6-4742-be98-41077bde45f4.jpeg?height=200","description":"<p>The Sunday Times’ tech correspondent brings on James Peyer, co-founder of Cambrian Biopharma, to talk about the unique structure of his startup (6:30), the goal (8:45), alighting on longevity as a 15-year-old (12:45), why the field has matured (15:40), what he chooses to focus on (19:50), getting drugs to market (24:55), raising money (32:00), why he chose the name (38:30), why dying of old age not necessarily an evolutionary inevitability (41:00), and the vaccine model (45:00),&nbsp;</p>","author_name":"The Sunday Times"}